Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03841357 · ClinicalTrials.gov registry record · Phase 3
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 121
- Enrollment target
NCT03841357 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 121 participants.
The verdict
NCT03841357, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.
Interventions
- OTHER Usual Care
- DRUG Abatacept Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2019-10-29 |
| Est. Completion | 2025-01-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03841357
The ClinicalTrials.gov registry entry for NCT03841357 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT03841357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03841357 about?
NCT03841357 is a clinical study titled "Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)". This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarth...
What is the current status of trial NCT03841357?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 121 participants. The study started on 2019-10-29. Estimated completion is 2025-01-22.
What interventions are being tested in trial NCT03841357?
The interventions under investigation include: Usual Care (OTHER), Abatacept Injection (DRUG).
Who is sponsoring clinical trial NCT03841357?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.